Karl Hazel
Karl Hazel has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Glen Doherty
Department of Gastroenterology, St Vincent’s University Hospital & School of Medicine, University College Dublin , Dublin
3 shared publications- Alaa El-Hussuna
Department of Surgery, Odda Hospital, Helse Fonna , Haugesund
2 shared publications - Anne Fennessy
Department of Gastroenterology St Vincent's University Hospital Dublin Ireland
2 shared publications - Anthony de Buck van Overstraeten
Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
2 shared publications - Bram Verstockt
Department of Gastroenterology and Hepatology University Hospitals Leuven KU Leuven Leuven Belgium
2 shared publications - Cara Dunne
Department of Gastroenterology, St. James's Hospital, Dublin, Ireland; Trinity Academic Gastroenterology Group, Trinity College Dublin, Ireland; Initiative IBD Research Network, Dublin, Ireland
2 shared publications
Latest Publications
- Top Cited Papers
- 7 July 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (7)
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
- 7 July 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (7)
Top Cited PapersECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
- 7 June 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (6)
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
This is the second of two articles presenting the European Crohn’s and Colitis Organisation [ECCO] evidence‑based consensus guidelines on the management of adult patients with ulcerative colitis [UC]. The first article covers the medical management of UC, including acute severe colitis. The present article addresses the surgical management of medically refractory UC, including the general surgical approach and perioperative optimisation, surgical strategies and techniques, and recommended levels of centre expertise and surgical specialisation. Together, these two articles aim to inform shared decision‑making and to guide clinicians and healthcare professionals involved in the care of patients with UC, drawing on the best available evidence.
- 7 June 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (6)
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
This is the second of two articles presenting the European Crohn’s and Colitis Organisation [ECCO] evidence‑based consensus guidelines on the management of adult patients with ulcerative colitis [UC]. The first article covers the medical management of UC, including acute severe colitis. The present article addresses the surgical management of medically refractory UC, including the general surgical approach and perioperative optimisation, surgical strategies and techniques, and recommended levels of centre expertise and surgical specialisation. Together, these two articles aim to inform shared decision‑making and to guide clinicians and healthcare professionals involved in the care of patients with UC, drawing on the best available evidence.
- Open Access
- 26 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1576
Preoperative Optimization for Elective Surgery in Crohn’s Disease: A Narrative Review
Crohn’s disease is a chronic inflammatory bowel disease and, despite an increase in the available drug treatments, many patients will still require surgery at some point in their disease course. Stricturing and penetrating phenotypes of Crohn’s disease are less likely to respond to our current medical treatment and, therefore, surgical intervention may be required. This is most commonly elective, planned surgery, thereby affording the opportunity to optimize medications, nutritional and inflammatory status, and steroid use. Poor nutritional status and previous surgery increase the risk of postoperative complications. Preoperative optimization has three main goals: reduction of postoperative complications; reduction of reoperation rates; and reduction of postoperative recurrence rates. A literature search was completed using PubMed, Embase, and Ovid using the search term “preoperative optimization in Crohn’s disease”, and it included both adult and pediatric studies, excluding those for perianal Crohn’s disease. In this narrative review, we examine the role of nutritional intervention, medical optimization pre and postoperatively, and the role of personalized prehabilitation in the reduction of postoperative complications. We demonstrate that these may all yield better postoperative outcomes for patients with Crohn’s disease undergoing elective surgery, although the evidence is somewhat limited and there is a requirement for more prospective randomized controlled trials to implement their role into standard practice or guidelines.
- 26 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1576
Open AccessPreoperative Optimization for Elective Surgery in Crohn’s Disease: A Narrative Review
Crohn’s disease is a chronic inflammatory bowel disease and, despite an increase in the available drug treatments, many patients will still require surgery at some point in their disease course. Stricturing and penetrating phenotypes of Crohn’s disease are less likely to respond to our current medical treatment and, therefore, surgical intervention may be required. This is most commonly elective, planned surgery, thereby affording the opportunity to optimize medications, nutritional and inflammatory status, and steroid use. Poor nutritional status and previous surgery increase the risk of postoperative complications. Preoperative optimization has three main goals: reduction of postoperative complications; reduction of reoperation rates; and reduction of postoperative recurrence rates. A literature search was completed using PubMed, Embase, and Ovid using the search term “preoperative optimization in Crohn’s disease”, and it included both adult and pediatric studies, excluding those for perianal Crohn’s disease. In this narrative review, we examine the role of nutritional intervention, medical optimization pre and postoperatively, and the role of personalized prehabilitation in the reduction of postoperative complications. We demonstrate that these may all yield better postoperative outcomes for patients with Crohn’s disease undergoing elective surgery, although the evidence is somewhat limited and there is a requirement for more prospective randomized controlled trials to implement their role into standard practice or guidelines.
- Open Access
- 6 November 2024
- Published by MDPI AG in Preprints.org
Preoperative Optimisation for Elective Surgery in Crohn’s Disease
Crohn’s disease is a chronic inflammatory bowel disease and despite an increase in the available drug treatments, many patients still require surgery at some point in their disease course. Stricturing and penetrating phenotypes of Crohn’s disease are less likely to respond to our current medical treatment and therefore, surgical intervention may be required. This is most commonly elective, planned surgery, thereby affording the opportunity to optimise medications, nutritional and inflammatory status, steroid use. Poor nutritional status and previous surgery increase the risk of postoperative complications. Preoperative optimisation has three main goals: reduction of postoperative complications, reduction of reoperation rates and reduction of postoperative recurrence rates. In this narrative review, we examine the role of nutritional intervention, medical optimisation pre- and postoperatively and the role of personalised prehabilitation in the reduction of postoperative complications.
- 6 November 2024
- Published by MDPI AG in Preprints.org
Open AccessPreoperative Optimisation for Elective Surgery in Crohn’s Disease
Crohn’s disease is a chronic inflammatory bowel disease and despite an increase in the available drug treatments, many patients still require surgery at some point in their disease course. Stricturing and penetrating phenotypes of Crohn’s disease are less likely to respond to our current medical treatment and therefore, surgical intervention may be required. This is most commonly elective, planned surgery, thereby affording the opportunity to optimise medications, nutritional and inflammatory status, steroid use. Poor nutritional status and previous surgery increase the risk of postoperative complications. Preoperative optimisation has three main goals: reduction of postoperative complications, reduction of reoperation rates and reduction of postoperative recurrence rates. In this narrative review, we examine the role of nutritional intervention, medical optimisation pre- and postoperatively and the role of personalised prehabilitation in the reduction of postoperative complications.
- 21 September 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (1) , 274-281
Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease
- 21 September 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (1) , 274-281
Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Tu1790 COMBINATION BIOLOGIC OR SMALL MOLECULE THERAPY IN INFLAMMATORY BOWEL DISEASE
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Tu1790 COMBINATION BIOLOGIC OR SMALL MOLECULE THERAPY IN INFLAMMATORY BOWEL DISEASE
- Open Access
- 13 January 2021
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 43 (4) , 540-541
The other ‘C’: Hospital-acquired Clostridioides difficile infection during the coronavirus disease 2019 (COVID-19) pandemic
- 13 January 2021
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 43 (4) , 540-541
Open AccessThe other ‘C’: Hospital-acquired Clostridioides difficile infection during the coronavirus disease 2019 (COVID-19) pandemic
- Open Access
- 1 January 2020
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 11
Emerging treatments for inflammatory bowel disease
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation, a relapsing and remitting clinical course, requirement for lifelong medication and often, significant morbidity. While multiple effective therapeutic options exist for the treatment of IBD, a proportion of patients will either fail to respond or lose response to therapy. Advances in therapeutics, such as the gut-specific anti-integrins, now offer patients an alternative option to systemic immunosuppression. Anti-interleukin 12 (anti-IL-12)/IL-23 agents offer new and effective treatment options for CD, while the oral small molecules now offer an oral alternative for the treatment of moderate-to-severe disease, previously requiring subcutaneous injection or intravenous infusion. Alternatives to pharmacological treatment such as stem-cell transplant and faecal microbiota transplant are also showing some promise in the treatment of both CD and UC.
- 1 January 2020
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 11
Open AccessEmerging treatments for inflammatory bowel disease
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation, a relapsing and remitting clinical course, requirement for lifelong medication and often, significant morbidity. While multiple effective therapeutic options exist for the treatment of IBD, a proportion of patients will either fail to respond or lose response to therapy. Advances in therapeutics, such as the gut-specific anti-integrins, now offer patients an alternative option to systemic immunosuppression. Anti-interleukin 12 (anti-IL-12)/IL-23 agents offer new and effective treatment options for CD, while the oral small molecules now offer an oral alternative for the treatment of moderate-to-severe disease, previously requiring subcutaneous injection or intravenous infusion. Alternatives to pharmacological treatment such as stem-cell transplant and faecal microbiota transplant are also showing some promise in the treatment of both CD and UC.